SurModics, Inc.

281 articles with SurModics, Inc.

• Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices

  4/1/2021

  Sublime™ Radial Access .014 RX PTA Dilatation Catheter, Sublime Radial Access Guide Sheath Deliver Outstanding Performance in Initial Physician Evaluations

• Surmodics to Present at Sidoti & Company Virtual Investor Conference

  3/17/2021

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, senior vice president of finance and chief financial officer, will make a presentation at the Sidoti & Company Virtual Investor Conference

• Surmodics Reports First Quarter Fiscal 2021 Results

  2/9/2021

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 first quarter ended December 31, 2020. Summary of First Quarter and Recent Highlights Revenue of $22.3 million, a decrease of 1% year-over-year

• Surmodics to Host Virtual Annual Meeting of Shareholders - Feb 04, 2021

  2/4/2021

  Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 11, at 4:00 p.m. CT, as a virtual meeting.

• Surmodics to Webcast First Quarter Fiscal 2021 Earnings Conference Call on February 9

  2/1/2021

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2021 conference call on Tuesday, February 9, at 7:30 a.m. CT (8:30 a.m. ET).

• 12-Month Data from Surmodics’ TRANSCEND Trial Presented at LINC 2021 Event

  1/25/2021

  Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from its TRANSCEND clinical trial has been presented at the Leipzig Interventional Course (LINC) 2021 virtual event.

• Surmodics Announces TRANSCEND Trial 12-Month Data to be Presented at LINC 2021 Virtual Event

  1/12/2021

  Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 12-month data from its TRANSCEND clinical trial will be presented at the upcoming Leipzig Interventional Course (LINC) 2021 virtual event.

• 6-Month Data From the Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020

  11/9/2020

  Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS first-in-human (FIH) study of the company’s Avess™ AV Fistula drug-coated balloon (DCB) was shared during a morning session at the Vascular Interventional Advances (VIVA) 2020 virtual conference.

• Surmodics Reports Fourth Quarter Fiscal 2020 Results

  11/4/2020

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended September 30, 2020.

• Surmodics Receives FDA 510(k) Clearance for Pounce™ Thrombus Retrieval System

  9/23/2020

  Surmodics Receives FDA 510(k) Clearance for Pounce™ Thrombus Retrieval System Next-generation technology provides easy, effective clot removal from peripheral arterial vasculature EDEN PRAIRIE, Minn.--( BUSINESS WIRE )-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Poun

• Surmodics Reports Third Quarter Fiscal 2020 Results

  8/5/2020

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 third quarter ended June 30, 2020.

• Surmodics Receives FDA 510(k) Clearance for Sublime™ Radial Access 0.014 RX PTA Dilatation Catheter

  8/5/2020

  Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sublime™ Radial Access 0.014 Rapid Exchange (RX) Percutaneous Transluminal Angioplasty (PTA) Dilatation Catheter.

• Surmodics to Webcast Third Quarter Fiscal 2020 Earnings Conference Call on August 5

  7/28/2020

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2020 conference call on Wednesday, August 5, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gary

• Surmodics Receives CE Mark for its SurVeil™ Drug Coated Balloon

  6/8/2020

  Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received CE Mark Certification in the European Union for its SurVeil™ drug-coated balloon (DCB). “I am excited about the potential of the SurVeil DCB to improve the

• Surmodics Names Gordon Weber as Senior Vice President of Legal, General Counsel and Secretary

  5/14/2020

  Surmodics Names Gordon Weber as Senior Vice President of Legal, General Counsel and Secretary

• Surmodics Reports Second Quarter Fiscal 2020 Results and Provides COVID-19 Pandemic Update

  4/29/2020

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 second quarter ended March 31, 2020, and suspended its financial guidance for fiscal 2020.

• Surmodics to Webcast Second Quarter Fiscal 2020 Earnings Conference Call on April 29

  4/21/2020

  Surmodics, Inc. today announced that it will host a live webcast of its second quarter fiscal 2020 conference call on Wednesday, April 29, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gar

• Surmodics to Host Virtual Annual Meeting of Shareholders - Feb. 6, 2020

  2/6/2020

  Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 13, at 4 p.m. CT, as a virtual meeting..

• Surmodics Reports First Quarter Fiscal 2020 Results

  2/5/2020

  Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 first quarter ended December 31, 2019.

• Surmodics Names Nusrath Sultana, MD, as Vice President, Clinical Affairs

  2/3/2020

  Surmodics, Inc. announced Nusrath Sultana, MD, has joined Surmodics as Vice President, Clinical Affairs, effective February 3, 2020.